The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aclaris Therapeutics, Inc. | COM | 00461U105 | 372 | 144,874 | SH | SOLE | 144,874 | 0 | 0 | ||
ALX Oncology Holdings Inc. | COM | 00166B105 | 36,740 | 973,514 | SH | SOLE | 973,514 | 0 | 0 | ||
Arbutus Biopharma Corp | COM | 03879J100 | 10,431 | 3,332,616 | SH | SOLE | 3,332,616 | 0 | 0 | ||
Cymabay Therapeutics, Inc. | COM | 23257D103 | 12,939 | 1,787,094 | SH | SOLE | 1,787,094 | 0 | 0 | ||
Cytokinetics Incorporated | COM | 23282W605 | 36,205 | 1,672,292 | SH | SOLE | 1,672,292 | 0 | 0 | ||
Generation Bio Co. | COM | 37148K100 | 26,519 | 857,939 | SH | SOLE | 857,939 | 0 | 0 | ||
Keros Therapeutics, Inc. | COM | 492327101 | 54,488 | 1,412,705 | SH | SOLE | 1,412,705 | 0 | 0 | ||
Kura Oncology, Inc. | COM | 50127T109 | 40,077 | 1,307,982 | SH | SOLE | 1,307,982 | 0 | 0 | ||
Myokardia, Inc. | COM | 62857M105 | 17,245 | 126,492 | SH | SOLE | 126,492 | 0 | 0 | ||
Nurix Therapeutics, Inc. | COM | 67080M103 | 81,969 | 2,348,014 | SH | SOLE | 2,348,014 | 0 | 0 | ||
Panacea Acquisition Corp | UNIT | 698102209 | 1,800 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | ||
Relay Therapeutics, Inc. | COM | 75943R102 | 91,116 | 2,139,380 | SH | SOLE | 2,139,380 | 0 | 0 | ||
Therapeutics Acquisition Corp | COM CL A | 88339T103 | 5,033 | 350,000 | SH | SOLE | 350,000 | 0 | 0 | ||
Vaxcyte, Inc. | COM | 92243G108 | 23,002 | 465,821 | SH | SOLE | 465,821 | 0 | 0 | ||
Voyager Therapeutics, Inc. | COM | 92915B106 | 5,514 | 516,751 | SH | SOLE | 516,751 | 0 | 0 |